Clinical Report: Prognostic Implications of Manual versus Digital PD-L1 Expression

Overview

This study investigates the prognostic significance of PD-L1 expression in pT3 and pT4 colon carcinoma using both manual and digital scoring methods. The findings suggest that the method of PD-L1 evaluation may influence survival outcomes, highlighting the need for standardized assessment in colorectal cancer.

Background

Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, and the role of PD-L1 as a prognostic marker remains controversial. Variability in PD-L1 expression evaluation methods contributes to inconsistent prognostic implications across studies. Understanding PD-L1's role in CRC could enhance treatment strategies, particularly with the advent of immunotherapy.

Data Highlights

No numerical data available in the source material.

Key Findings

• PD-L1 expression has been correlated with worse survival in various solid tumors.
• The prognostic value of PD-L1 in colorectal cancer is influenced by the method of evaluation (manual vs digital).
• Subgroup analysis based on mismatch repair (MMR) status reveals differing prognostic implications.
• Standardized approaches for PD-L1 evaluation in CRC are lacking, leading to mixed results in existing literature.
• Current guidelines do not recommend routine PD-L1 testing for diagnosis or treatment selection in colon cancer.

Clinical Implications

Clinicians should be aware of the variability in PD-L1 expression evaluation methods and their potential impact on patient prognosis. Standardized protocols for PD-L1 assessment in colorectal cancer are necessary to improve the reliability of prognostic predictions and treatment decisions.

Conclusion

The study underscores the importance of methodical evaluation of PD-L1 expression in colon carcinoma, as it may significantly affect survival outcomes. Further research is needed to establish standardized guidelines for PD-L1 assessment in clinical practice.

References

1. Gastric Cancer, Enhanced Scoring of PD-L1 in Gastric Carcinoma, 2021
2. The Role of Programmed Death Ligand 1 (PD-L1) in Colorectal Cancer, 2021
3. The presence of poorly differentiated clusters in metastatic lymph nodes as a prognostic indicator for survival in patients with pStage III colorectal cancer, 2015
4. NCCN Clinical Practice Guidelines in Oncology, 2025
5. ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer, 2024
6. The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy, 2023
7. Journal of Gastroenterology — Influence of the Tumor Microbiome on Immune Response and Outcomes in Human Pancreatic Ductal Adenocarcinoma
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
9. ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer | memo - Magazine of European Medical Oncology | Springer Nature Link
10. The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types - PMC